Shifts in subsets of CD8+ T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control study
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Shifts in CD8+ T-cell subsets that are hallmarks of immunosenescence are observed in ageing and in conditions of chronic immune stimulation. Presently, there is limited documentation of such changes in lung cancer and other malignancies affecting the lungs. METHODS: Changes in CD8+ T-cell subsets, based on the expression of CD28 and CD57, were analysed in patients with various forms of cancer affecting the lungs, undergoing chemotherapy and in a control group over six months, using multi-colour flow cytometry. RESULTS: The differences between patients and controls, and the changes in the frequency of CD8+ T-cell subpopulations among lung cancer patients corresponded to those seen in immunosenescence: lower CD8-/CD8+ ratio, lower proportions of CD28+CD57- cells consisting of naïve and central memory cells, and higher proportions of senescent-enriched CD28-CD57+ cells among the lung cancer patients, with the stage IV lung cancer patients showing the most pronounced changes. Also observed was a tendency of chemotherapy to induce the formation of CD28+CD57+ cells, which, in line with the capacity of chemotherapy to induce the formation of senescent cells, might provide more evidence supporting CD28+CD57+ cells as senescent cells. CONCLUSION: Immunosenescence was present before the start of the treatment; it appeared to be pronounced in patients with advanced cases of malignancies affecting the lungs, and might not be averted by chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenchley, J. M., Karandikar, N. J., Betts, M. R., Ambrozak, D. R., Hill, B. J., Crotty, L. E., Casazza, J. P., Kuruppu, J., Migueles, S. A., Connors, M., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2103 · Cited by 1,073 · cited 6×
“While the CD28-CD57+ cells, also considered as terminally differentiated effector memory cells, and the CD28-CD57- cells, considered as effector memory cells, might not provide good anti-tumour immunity but more adverse effects, the CD28+CD57- cells, because of their enrichment with naïve and central memory cells, and…”
BackgroundMethodInfluentialUnderstanding immunosenescence to improve responses to vaccines
Goronzy, J. J., & Weyand, C. M. (2013) · Nature Immunology · doi:10.1038/ni.2588 · Cited by 827 · cited 1×
“Immunosenescence has been shown to increase with chronological age among normal adults, even without any disease interference [3, 50, 60].”
BackgroundTherapy-induced senescence in cancer.
Ewald, J. A., Desotelle, J. A., Wilding, G., & Jarrard, D. F. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq364 · Cited by 824 · cited 2×
“lar senescence is enhanced by DNA damaging chemotherapy [24, 25].”
BackgroundCD8 + T‐cell memory in tumor immunology and immunotherapy
Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00391.x · Cited by 511 · cited 1×
“Cancer patients with advanced disease usually experience decline in naïve and central memory T-cells [48].”
BackgroundImmune Activation and CD8+ T-Cell Differentiation towards Senescence in HIV-1 Infection
Papagno, L., Spina, C. A., Marchant, A., Salio, M., Rufer, N., Little, S., Dong, T., Chesney, G., Waters, A., Easterbrook, P., et al. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020020 · Cited by 478 · cited 5×
“Abbreviations 7-AAD: 7-amino actinomycin-D; BSA-PBS: buffering solution; CD: Cisplatin & docetaxel; CDK: Cyclin dependent kinase; CE: Cisplatin & etoposide; CG: Cisplatin & gemcitabine; CMV: Cytomegalovirus; CP: Cisplatin & pemetrexed; CV: Cisplatin & vinorelbine; FITC: Fluorescein isothiocyanate; HIV: Human immunodef…”
BackgroundInfluentialT cell subset-specific susceptibility to aging
Czesnikiewicz-Guzik, M., Lee, W.-W., Cui, D., Hiruma, Y., Lamar, D. L., Yang, Z.-Z., Ouslander, J. G., Weyand, C. M., & Goronzy, J. J. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.12.002 · Cited by 478 · cited 2×
“Others and our group have shown that the expression of CD57 (found on both CD28CD57+ and CD28+CD57+ cells) was associated with pronounced characteristics of senescent cells such as loss of proliferation capacity in vitro, telomere attrition, increased expression of cyclin dependent kinase (CDK) inhibitors – p16 and p2…”
BackgroundOlsson, J., Wikby, A., Johansson, B., Löfgren, S., Nilsson, B.-O., & Ferguson, F. G. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(00)00210-4 · Cited by 474 · cited 3×
“IRP has an unfavourable prognosis and often results in a shortened life expectancy [17, 50].”
BackgroundEffect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients With Breast Cancer
Sanoff, H. K., Deal, A. M., Krishnamurthy, J., Torrice, C., Dillon, P., Sorrentino, J., Ibrahim, J. G., Jolly, T. A., Williams, G., Carey, L. A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju057 · Cited by 283 · cited 1×
“An enhanced expression of markers of cellular senescence in T-lymphocytes has recently been shown in breast cancer patients treated with DNA-damaging agents [51].”
BackgroundImmunosenescence and vaccine failure in the elderly
Grubeck-Loebenstein, B., Della Bella, S., Iorio, A. M., Michel, J.-P., Pawelec, G., & Solana, R. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03324904 · Cited by 269
Cytomegalovirus Infection: A Driving Force in Human T Cell Immunosenescence
KOCH, S., LARBI, A., ÖZCELIK, D., SOLANA, R., GOUTTEFANGEAS, C., ATTIG, S., WIKBY, A., STRINDHALL, J., FRANCESCHI, C., & PAWELEC, G. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1396.043 · Cited by 242
Cited by
How the ageing microenvironment influences tumour progression
Fane, M., & Weeraratna, A. T. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0222-9 · Cited by 849
Tumour burden and efficacy of immune-checkpoint inhibitors
Dall’Olio, F. G., Marabelle, A., Caramella, C., Garcia, C., Aldea, M., Chaput, N., Robert, C., & Besse, B. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00564-3 · Cited by 350
Effector, Memory, and Dysfunctional CD8+T Cell Fates in the Antitumor Immune Response
Reiser, J., & Banerjee, A. (2016) · Journal of Immunology Research · doi:10.1155/2016/8941260 · Cited by 255
The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology
Huff, W. X., Kwon, J. H., Henriquez, M., Fetcko, K., & Dey, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112810 · Cited by 217
“Gained expression of CD57, also known as HNK-1 (human natural killer-1), is a common feature associated with circulating senescent T cells, and increased CD8+CD28−CD57+ senescent T cells were identified in multiple pathological conditions, including HIV infection, multiple myeloma, lung cancer, and chronic inflammatio…”
BackgroundFerrara, R., Mezquita, L., Auclin, E., Chaput, N., & Besse, B. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.003 · Cited by 163
Metadata
- Authors
- Onyema, O. O., Decoster, L., Njemini, R., Forti, L. N., Bautmans, I., De Waele, M., & Mets, T.
- Venue
- BMC Cancer
- Published
- 2015-12
- Volume
- 15
- Issue
- 1
- Pages
- 1016-1016
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2203507673
- Cited by
- 38
- References
- 16
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Shifts in subsets of CD8+ T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control study. https://app.cochat.ai/papers/10.1186/s12885-015-2013-3
- The paper
- Onyema, O. O., Decoster, L., Njemini, R., Forti, L. N., Bautmans, I., De Waele, M., & Mets, T. (2015). Shifts in subsets of CD8+ T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control study. BMC Cancer. https://doi.org/10.1186/s12885-015-2013-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.